--- title: "20:47 ETNASDAQ: QURE: Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against uniQure N.V." description: "Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. (NASDAQ: QURE) on behalf of investors who purchased shares between September 24, 2025, and Oct" type: "news" locale: "en" url: "https://longbridge.com/en/news/276292336.md" published_at: "2026-02-19T01:48:56.000Z" --- # 20:47 ETNASDAQ: QURE: Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against uniQure N.V. > Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. (NASDAQ: QURE) on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025. The lawsuit alleges that uniQure misled investors regarding its Huntington's disease gene therapy drug, AMT-130, and its clinical trial results. Investors can seek lead plaintiff status by April 13, 2026, and are encouraged to contact KTMC for legal assistance. **Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025?** **Affected uniQure N.V.** **Investor Summary** - **Who**: uniQure N.V. (NASDAQ: QURE) - **What:** Securities fraud class action lawsuit filed - **Class Period:** September 24, 2025, and October 31, 2025 - **Deadline to Seek Lead Plaintiff Status:** April 13, 2026 - **Key Lawsuit Allegations:** Material misstatements and/or omissions concerning the company's Huntington's disease gene therapy drug. - **Investor Action:** Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options at no cost to investor , /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against uniQure N.V. (NASDAQ: QURE) (uniQure) on behalf of investors who purchased or acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025, inclusive (the Class Period). This action, captioned *Scocco v. uniQure N.V., et al.*, Case No. 1:26-cv-01124, was filed in the United States District Court for the Southern District of New York. ***Important Deadline Reminder: Investors who purchased or otherwise acquired uniQure ordinary shares during the Class Period may, no later than April 13, 2026, move the Court to serve as lead plaintiff for the class.*** **CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:** If you purchased or acquired uniQure ordinary shares and experienced losses, you are encouraged to contact KTMC attorney Jonathan Naji, Esq. at: 📞 (484) 270-1453 📧 \[email protected\] 🌐 https://www.ktmc.com/qure-uniqure-nv-class-action-lawsuit?utm\_source=PR\_Newswire&utm\_medium=pressrelease&utm\_campaign=qure&mktm=PR There is no cost or obligation to speak with an attorney. **UNIQURE N.V.** **CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:** uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel gene therapy being developed to slow the progression of HD. During the Class Period, uniQure misled investors about its Phase I/II clinical trials (Pivotal Study) of AMT-130 as well as the prospects and timeline of uniQure's Biologics License Application (BLA) submission to the FDA for approval to use AMT-130 to treat patients with HD. The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about uniQure's business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) the design of uniQure's Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was not fully approved by the FDA; (2) Defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its BLA timeline to perform additional studies to supplement its BLA submission; and (3) as a result, Defendants' statements about uniQure's business, operations, and prospects lacked a reasonable basis. **WHAT QURE INVESTORS CAN DO NOW:** 1. File to be lead plaintiff by April 13, 2026. 2. Contact KTMC for a free case evaluation. 3. Retain counsel of choice or take no action. **THE LEAD PLAINTIFF PROCESS FOR UNIQURE N.V. INVESTORS****:** uniQure investors may, ***no later than April 13, 2026,*** seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages uniQure investors to contact the firm for more information. **ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):** Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com. **CONTACT: **Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 \[email protected\] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. SOURCE Kessler Topaz Meltzer & Check, LLP ### Related Stocks - [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md) - [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md) - [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md) - [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md) - [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md) - [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md) - [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md) - [QURE.US - Uniqure](https://longbridge.com/en/quote/QURE.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 關鍵事實：ImmunityBio 已完成第二階段試驗的招募工作；電話會議已安排 | ImmunityBio 已經提前完成了其第二階段 Quilt 2.005 試驗的招募，該試驗評估 Anktiva 和 BCG 對早期膀胱癌的療效，顯示出改善的無癌率。ImmunityBio, Inc. 將於 2026 年 3 月 3 日下午 | [Link](https://longbridge.com/en/news/277243866.md) | | Nuvation Bio 的盈利概況 | Nuvation Bio（紐約證券交易所代碼：NUVB）將於 2026 年 3 月 2 日公佈季度財報，分析師預計每股收益（EPS）為-0.07 美元。儘管最近出現了每股收益未達預期的情況，導致股價下跌 6.58%，但該公司過去一年股價仍上 | [Link](https://longbridge.com/en/news/277235801.md) | | ImmunityBio 的董事出售了 75,000 股股票 | ImmunityBio 董事 Simon Barry J. 於 2026 年 2 月 24 日以每股平均價格 12.0105 美元出售了 75,000 股普通股，總計 900,787 美元。此次出售是在 2024 年 9 月 4 日建立的 | [Link](https://longbridge.com/en/news/277125041.md) | | Alpha Teknova：第四季度財報分析 | Alpha Teknova（納斯達克代碼：TKNO）於 2026 年 2 月 26 日公佈了其第四季度財報，實際每股收益（EPS）為-$0.09，未能達到預期收益，差距為 0.0%。與去年相比，收入增加了 71.9 萬美元，總計 1045 | [Link](https://longbridge.com/en/news/277095859.md) | | Brent Sabatini 出售了 1,430 股 Vir Biotechnology（納斯達克代碼：VIR）的股票 | Vir Biotechnology 的首席行政官 Brent Sabatini 於 2 月 24 日以每股 9.53 美元的價格出售了 1,430 股，總計 13,627.90 美元，減少了 2.01% 的持股比例。董事 Vicki Sat | [Link](https://longbridge.com/en/news/277221019.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.